GH Research (NASDAQ:GHRS) Shares Up 1.4% – Here’s What Happened

GH Research PLC (NASDAQ:GHRS)’s share price shot up 1.4% on Monday . The stock traded as high as $9.72 and last traded at $9.40. 10,151 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 79,479 shares. The stock had previously closed at $9.27.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. JMP Securities reissued a “market outperform” rating and set a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group decreased their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th.

GH Research Stock Up 2.0 %

The business has a 50-day simple moving average of $7.95 and a 200-day simple moving average of $10.24. The company has a market cap of $482.84 million, a PE ratio of -11.39 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, equities research analysts predict that GH Research PLC will post -0.79 EPS for the current fiscal year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. boosted its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the quarter. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).